Study to Investigate the Safety of the Transplantation of Human Glial

Status Recruiting

Clinical Trial Summary

This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects with Transverse Myelitis. For each of the dose levels, transplantation of Q-Cells® unilaterally into spinal cord demyelinated lesions will be evaluated. Subjects will be blinded to side of treatment. Idiopathic Transverse Myelitis is a monophasic disorder characterized predominantly by demyelination. Patients are left with disability from damage to ascending and descending white matter tracts. Q-Cells® are comprised of glial progenitor cells.It is postulated that the Q-Cells® glial progeny (healthy astrocytes and oligodendrocytes) will integrate into the spinal cord lesion site and remyelinate demyelinated axons as well as provide trophic support for damaged axons. Therefore, Q-Cells® have the potential to repair damage that has occurred and could be clinically useful for patients with disability caused by TM. The study is planned to enroll up to 9 subjects. Each subject will be followed for 9 months after transplantation of Q-Cells®. Each subject will receive a single time point administration of Q-Cells®: with transplantation foci targeted to posterior columns in the spinal cord (all transplantation foci below C7) on one side. Study participation consists of Screening, Pre-operative/Treatment, and Post-treatment study periods that will generally last from 9 to 12 months in total. The study data will be assessed for safety and activity until the last subject has completed the 9-month study visit. Following completion of the 9-month follow-up period, subjects who consent will continue to be followed for safety and activity in a separate long-term follow-up protocol.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03887273
Study type	Interventional
Source	Q Therapeutics, Inc.
Contact	Taylor Hinojo
Phone	214-645-3230
Email	taylor.hinojo@utsouthwestern.edu
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	September 20, 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04721717` - AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
Recruiting	`NCT05630313` - Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
Completed	`NCT03942952` - PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Recruiting	`NCT06147258` - The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury	N/A
Active, not recruiting	`NCT00445367` - Biobank For MS And Other Demyelinating Diseases
Recruiting	`NCT01623076` - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
Terminated	`NCT01446575` - Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis	Phase 4
Active, not recruiting	`NCT04564495` - Home Based Tele-exercise for People With Chronic Neurological Impairments	N/A
Enrolling by invitation	`NCT00704626` - Serum Auto-Antibodies in Neurological Diseases
Completed	`NCT02341950` - Clinical Trial of a Serious Game for Individuals With SCI/D	N/A
Completed	`NCT02166346` - Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)	Phase 2
Completed	`NCT00179478` - Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis	Phase 4
Completed	`NCT03336762` - Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis
Recruiting	`NCT05249595` - Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance	N/A
Not yet recruiting	`NCT06055998` - Frequency ,Etiology and Prognostic Factors of Acute Transverse Myelitis
Enrolling by invitation	`NCT06163508` - A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells
Completed	`NCT03138421` - Central Pain Study for ABX-1431	Phase 1
Recruiting	`NCT05017142` - Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms